Prelude inks first partnership on cancer drugs
Share
WILMINGTON – Prelude Therapeutics is one of Delaware’s burgeoning life science success stories, and it recently announced a new milestone in signing its first partnership agreement with a major Canadian drug development firm, AbCellera. The multi-year, multi-program partnership aims to discover, develop, and commercialize potentially first-in-class treatments for patients with cancer. Such partnerships are common
Want to Read More?
Paid DBT subscribers get unlimited access to all Insider content and much more. Learn more in our Insider FAQ.
Already an Insider? Log In.